Hiromi Wada
Research Subjects
Hiromi Wada has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
Fumihiro Tanaka
Department of Thoracic Surgery, Faculty of Medicine, Kyoto University, Shogoin-kawahara-cho 53, Sakyo-ku, Kyoto 606-8397, Japan
7 shared publicationsRyo Miyahara
Department of Thoracic Surgery, Kyoto University Hospital, 54 Kawahara-cho, Kyoto 606-8507, Japan
7 shared publicationsKazuhiro Yanagihara
Department of Thoracic Surgery, Faculty of Medicine, Kyoto University, Shogoin-kawahara-cho 53, Sakyo-ku, Kyoto 606-8397, Japan
6 shared publications- Reo Hamaguchi
Japanese Society on Inflammation and Metabolism in Cancer, 119 Nishioshikouji-cho, Nakagyo-ku, Kyoto 604-0842, Japan
6 shared publications - Hiromasa Morikawa
Japanese Society on Inflammation and Metabolism in Cancer, 119 Nishioshikouji-cho, Nakagyo-ku, Kyoto 604-0842, Japan
5 shared publications - Masahide Isowa
Japanese Society on Inflammation and Metabolism in Cancer, 119 Nishioshikouji-cho, Nakagyo-ku, Kyoto 604-0842, Japan
5 shared publications
Latest Publications
- Open Access
- 7 August 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1867616
Association of alkalization therapy with long-term survival in stage IV or recurrent colorectal cancer: interaction with RAS mutation status
Background: Stage IV or recurrent colorectal cancer remains difficult to treat, especially in patients with RAS-mutant tumors, for whom anti-EGFR antibodies are not effective. Increasing evidence indicates that acidification of the tumor microenvironment promotes invasion, metastasis, therapeutic resistance, and immune suppression. Alkalization therapy has therefore attracted interest as a supportive strategy to improve systemic acid-base and metabolic conditions. Methods: We retrospectively analyzed patients with stage IV or recurrent colorectal cancer who first visited Karasuma Wada Clinic between 2014 and 2019 and underwent alkalization therapy with at least three urinary pH measurements. Two patients with BRAF-mutant tumors were excluded, leaving 129 patients for the primary analysis. Urinary pH was summarized using the 25% chronologically trimmed mean urinary pH. Overall survival (OS) was the primary endpoint. Among 80 patients with known RAS mutation status, a Cox proportional hazards model including interaction terms for urinary pH × RAS mutation status and urinary pH × liver metastasis was used as the primary analysis, followed by Kaplan-Meier analyses guided by the interaction structure. Results: In the overall cohort, the 5-year OS rate was 0.212 (95% CI, 0.113-0.362). Among the 80 patients with known RAS status, the interaction between urinary pH and RAS mutation status was significant (HR, 0.22; 95% CI, 0.06-0.78; likelihood ratio test, p = 0.0199), indicating that the prognostic impact of urinary pH differed according to molecular background. The 5-year OS rates were 0.250 in the RAS wild-type group and 0.130 in the RAS mutation-positive group. Within the RAS mutation-positive subgroup, patients with urinary pH ≥7.0 had significantly better OS than those with urinary pH <7.0 (Gehan-Breslow-Wilcoxon test, p = 0.013). Among patients with both RAS mutation-positive disease and liver metastases, urinary pH ≥7.0 was likewise associated with significantly longer OS (log-rank p = 0.0141). Conclusions: Maintenance of urinary pH ≥7.0 under alkalization therapy was associated with longer survival in stage IV or recurrent colorectal cancer, particularly in clinically unfavorable subgroups defined by RAS mutation and liver metastasis. These findings support prospective evaluation of alkalization-oriented intervention as a complementary therapeutic strategy.
- 7 August 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1867616
Open AccessAssociation of alkalization therapy with long-term survival in stage IV or recurrent colorectal cancer: interaction with RAS mutation status
Background: Stage IV or recurrent colorectal cancer remains difficult to treat, especially in patients with RAS-mutant tumors, for whom anti-EGFR antibodies are not effective. Increasing evidence indicates that acidification of the tumor microenvironment promotes invasion, metastasis, therapeutic resistance, and immune suppression. Alkalization therapy has therefore attracted interest as a supportive strategy to improve systemic acid-base and metabolic conditions. Methods: We retrospectively analyzed patients with stage IV or recurrent colorectal cancer who first visited Karasuma Wada Clinic between 2014 and 2019 and underwent alkalization therapy with at least three urinary pH measurements. Two patients with BRAF-mutant tumors were excluded, leaving 129 patients for the primary analysis. Urinary pH was summarized using the 25% chronologically trimmed mean urinary pH. Overall survival (OS) was the primary endpoint. Among 80 patients with known RAS mutation status, a Cox proportional hazards model including interaction terms for urinary pH × RAS mutation status and urinary pH × liver metastasis was used as the primary analysis, followed by Kaplan-Meier analyses guided by the interaction structure. Results: In the overall cohort, the 5-year OS rate was 0.212 (95% CI, 0.113-0.362). Among the 80 patients with known RAS status, the interaction between urinary pH and RAS mutation status was significant (HR, 0.22; 95% CI, 0.06-0.78; likelihood ratio test, p = 0.0199), indicating that the prognostic impact of urinary pH differed according to molecular background. The 5-year OS rates were 0.250 in the RAS wild-type group and 0.130 in the RAS mutation-positive group. Within the RAS mutation-positive subgroup, patients with urinary pH ≥7.0 had significantly better OS than those with urinary pH <7.0 (Gehan-Breslow-Wilcoxon test, p = 0.013). Among patients with both RAS mutation-positive disease and liver metastases, urinary pH ≥7.0 was likewise associated with significantly longer OS (log-rank p = 0.0141). Conclusions: Maintenance of urinary pH ≥7.0 under alkalization therapy was associated with longer survival in stage IV or recurrent colorectal cancer, particularly in clinically unfavorable subgroups defined by RAS mutation and liver metastasis. These findings support prospective evaluation of alkalization-oriented intervention as a complementary therapeutic strategy.
- Open Access
Tumor Microenvironment Acidosis and Alkalization-Oriented Interventions in Advanced Solid Tumors: A Narrative Review and Science-Based Medicine Perspective on Long-Tail Survival
Median overall survival remains a central endpoint in oncology, but it can obscure a clinically meaningful long tail of patients with advanced solid tumors who survive well beyond the median. One biological context in which this pattern may be relevant is tumor microenvironment (TME) acidosis. Driven by aerobic glycolysis, hypoxia, impaired perfusion, and proton-export programs, acidic TME is increasingly implicated in invasion, therapeutic resistance, and immune suppression. This narrative review examines TME acidosis as the primary biological framework and considers long-tail survival as a clinical lens through which its implications may be interpreted. We summarize the biological basis and heterogeneity of acidic TME, review current approaches to clinical and translational assessment of tumor acidity, including acidoCEST magnetic resonance imaging (MRI) and positron emission tomography (PET)-based approaches, and discuss the potential and limitations of alkalization-oriented interventions such as buffering and diet-based strategies. Particular attention is given to the distinction between direct measurements of tumor acidity and clinically feasible but indirect markers such as urinary pH, which should not be interpreted as a direct surrogate for local tumor extracellular pH. From a science-based medicine perspective, long-tail survival is treated here as a hypothesis-generating clinical signal rather than proof of causality. Overall, alkalization-oriented interventions appear biologically plausible and clinically testable, but current clinical evidence remains limited and context-dependent. Future progress will require mechanistically informed biomarkers, careful safety evaluation, and trial designs capable of detecting delayed separation of survival curves and tail-oriented patterns of benefit.
Open AccessTumor Microenvironment Acidosis and Alkalization-Oriented Interventions in Advanced Solid Tumors: A Narrative Review and Science-Based Medicine Perspective on Long-Tail Survival
Median overall survival remains a central endpoint in oncology, but it can obscure a clinically meaningful long tail of patients with advanced solid tumors who survive well beyond the median. One biological context in which this pattern may be relevant is tumor microenvironment (TME) acidosis. Driven by aerobic glycolysis, hypoxia, impaired perfusion, and proton-export programs, acidic TME is increasingly implicated in invasion, therapeutic resistance, and immune suppression. This narrative review examines TME acidosis as the primary biological framework and considers long-tail survival as a clinical lens through which its implications may be interpreted. We summarize the biological basis and heterogeneity of acidic TME, review current approaches to clinical and translational assessment of tumor acidity, including acidoCEST magnetic resonance imaging (MRI) and positron emission tomography (PET)-based approaches, and discuss the potential and limitations of alkalization-oriented interventions such as buffering and diet-based strategies. Particular attention is given to the distinction between direct measurements of tumor acidity and clinically feasible but indirect markers such as urinary pH, which should not be interpreted as a direct surrogate for local tumor extracellular pH. From a science-based medicine perspective, long-tail survival is treated here as a hypothesis-generating clinical signal rather than proof of causality. Overall, alkalization-oriented interventions appear biologically plausible and clinically testable, but current clinical evidence remains limited and context-dependent. Future progress will require mechanistically informed biomarkers, careful safety evaluation, and trial designs capable of detecting delayed separation of survival curves and tail-oriented patterns of benefit.
- Open Access
- 29 January 2026
- Published by MDPI AG in Preprints.org
Tumor Microenvironment Acidosis and Alkalization-Oriented Interventions in Advanced Solid Tumors: A Narrative Review and Science-Based Medicine Perspective on Long-Tail Survival
Median overall survival (OS) is a useful summary statistic in oncology, but it can obscure a clini-cally important and recurring phenomenon: a non-negligible fraction of patients with advanced (stage IV) solid tumors survive far beyond the median, forming a long tail on the survival curve. Accumulating mechanistic evidence indicates that tumor microenvironment (TME) acido-sis—driven by aerobic glycolysis, hypoxia, and proton-export systems (e.g., NHE1, monocarbox-ylate transporters, carbonic anhydrase IX, and V-ATPase)—promotes invasion, therapy resistance, and immune suppression. Buffering and other alkalization strategies can partially neutralize acidic TME in preclinical models and may enhance antitumor immunity, suggesting that modulating extracellular pH (pHe) is a plausible system-level lever. Science-based medicine (SBM) provides a complementary framework to evidence-based medicine (EBM) by integrating population-level evidence with causal mechanisms and longitudinal patient data, viewing cancer as a complex, non-equilibrium system with multiple attractor states. From this perspective, long-tail survival is not merely an outlier but may represent a qualitative state transition of the tumor–host system. We summarize key biology of TME acidosis, review alkalization-oriented interventions and their translational challenges, and discuss implications for trial design, including endpoints and analyses that capture delayed separation of survival curves and tail effects.
- 29 January 2026
- Published by MDPI AG in Preprints.org
Open AccessTumor Microenvironment Acidosis and Alkalization-Oriented Interventions in Advanced Solid Tumors: A Narrative Review and Science-Based Medicine Perspective on Long-Tail Survival
Median overall survival (OS) is a useful summary statistic in oncology, but it can obscure a clini-cally important and recurring phenomenon: a non-negligible fraction of patients with advanced (stage IV) solid tumors survive far beyond the median, forming a long tail on the survival curve. Accumulating mechanistic evidence indicates that tumor microenvironment (TME) acido-sis—driven by aerobic glycolysis, hypoxia, and proton-export systems (e.g., NHE1, monocarbox-ylate transporters, carbonic anhydrase IX, and V-ATPase)—promotes invasion, therapy resistance, and immune suppression. Buffering and other alkalization strategies can partially neutralize acidic TME in preclinical models and may enhance antitumor immunity, suggesting that modulating extracellular pH (pHe) is a plausible system-level lever. Science-based medicine (SBM) provides a complementary framework to evidence-based medicine (EBM) by integrating population-level evidence with causal mechanisms and longitudinal patient data, viewing cancer as a complex, non-equilibrium system with multiple attractor states. From this perspective, long-tail survival is not merely an outlier but may represent a qualitative state transition of the tumor–host system. We summarize key biology of TME acidosis, review alkalization-oriented interventions and their translational challenges, and discuss implications for trial design, including endpoints and analyses that capture delayed separation of survival curves and tail effects.
- Open Access
- 21 January 2026
- Published by Elsevier in Translational Oncology
- Vol. 65, 102677
Five-year survival of patients with non-small cell lung cancer treated with alkalization therapy
- 21 January 2026
- Published by Elsevier in Translational Oncology
- Vol. 65, 102677
Open AccessFive-year survival of patients with non-small cell lung cancer treated with alkalization therapy
- Open Access
- 23 April 2025
- Published by Walter de Gruyter GmbH in Oncologie
- Vol. 27 (3) , 393-401
Cancer can be suppressed by alkalizing the tumor microenvironment: the effectiveness of “alkalization therapy” in cancer treatment
Objectives: The abnormal metabolism of cancer cells, referred to as the Warburg effect, creates acidic tumor microenvironments (TME) that can contribute to treatment resistance and cancer progression. “Alkalization therapy”, which involves dietary changes, aims to reduce acidity by lowering the potential renal acid load. This study aims to analyze 5-year survival rates of cancer patients undergoing alkalization therapy and compare survival rates among various urine pH levels. Methods: A total of 1,100 patients with stage IV cancers who first visited Karasuma Wada Clinic between January 2014 and December 2023 were retrospectively analyzed. The Kaplan–Meier method, log-rank test, and Cox proportional hazards model were used for statistical analyses. Results: The overall 5-year survival rate was 37.7 %, including 7.9 % for pancreatic cancer, 44.3 % for breast cancer, and 48.6 % for non-small cell lung cancer (NSCLC). For pancreatic cancer, urine pH was the only significant prognostic factor, with a hazard ratio of 0.55 (95 % CI: 0.36–0.83, p=0.004). The 5-year survival rates of patients categorized by urine pH levels (pH≤5.5, 5.5<pH<7.5, and pH≥7.5) showed significant differences in patients with pancreatic and breast cancer (p5.5) showed a significant difference in overall survival (p=0.0434). Conclusions: Alkalization therapy is a promising cancer treatment that complements standard therapies. Raising urine pH may optimize TME and enhance survival outcomes.
- 23 April 2025
- Published by Walter de Gruyter GmbH in Oncologie
- Vol. 27 (3) , 393-401
Open AccessCancer can be suppressed by alkalizing the tumor microenvironment: the effectiveness of “alkalization therapy” in cancer treatment
Objectives: The abnormal metabolism of cancer cells, referred to as the Warburg effect, creates acidic tumor microenvironments (TME) that can contribute to treatment resistance and cancer progression. “Alkalization therapy”, which involves dietary changes, aims to reduce acidity by lowering the potential renal acid load. This study aims to analyze 5-year survival rates of cancer patients undergoing alkalization therapy and compare survival rates among various urine pH levels. Methods: A total of 1,100 patients with stage IV cancers who first visited Karasuma Wada Clinic between January 2014 and December 2023 were retrospectively analyzed. The Kaplan–Meier method, log-rank test, and Cox proportional hazards model were used for statistical analyses. Results: The overall 5-year survival rate was 37.7 %, including 7.9 % for pancreatic cancer, 44.3 % for breast cancer, and 48.6 % for non-small cell lung cancer (NSCLC). For pancreatic cancer, urine pH was the only significant prognostic factor, with a hazard ratio of 0.55 (95 % CI: 0.36–0.83, p=0.004). The 5-year survival rates of patients categorized by urine pH levels (pH≤5.5, 5.5<pH<7.5, and pH≥7.5) showed significant differences in patients with pancreatic and breast cancer (p5.5) showed a significant difference in overall survival (p=0.0434). Conclusions: Alkalization therapy is a promising cancer treatment that complements standard therapies. Raising urine pH may optimize TME and enhance survival outcomes.
- 6 November 2024
- Published by Springer Nature
- p. 523-540
Alkalinising of the Acidic Tumour Microenvironment Makes Cancer Treatment Easier and Milder
- 6 November 2024
- Published by Springer Nature
- p. 523-540
Alkalinising of the Acidic Tumour Microenvironment Makes Cancer Treatment Easier and Milder
- Open Access
- 26 September 2024
- Published by MDPI AG in Biomedicines
- Vol. 12 (10) , 2197
How Does Cancer Occur? How Should It Be Treated? Treatment from the Perspective of Alkalization Therapy Based on Science-Based Medicine
This review article investigates the relationship between mitochondrial dysfunction and cancer progression, emphasizing the metabolic shifts that promote tumor growth. Mitochondria are crucial for cellular energy production, but they also play a significant role in cancer progression by promoting glycolysis even under oxygen-rich conditions, a phenomenon known as the Warburg effect. This metabolic reprogramming enables cancer cells to maintain an alkaline internal pH and an acidic external environment, which are critical for their proliferation and survival in hypoxic conditions. The article also explores the acidic tumor microenvironment (TME), a consequence of intensive glycolytic activity and proton production by cancer cells. This acidic milieu enhances the invasiveness and metastatic potential of cancer cells and contributes to increased resistance to chemotherapy. Alkalization therapy, which involves neutralizing this acidity through dietary modifications and the administration of alkalizing agents such as sodium bicarbonate, is highlighted as an effective strategy to counteract these adverse conditions and impede cancer progression. Integrating insights from science-based medicine, the review evaluates the effectiveness of alkalization therapy across various cancer types through clinical assessments. Science-based medicine, which utilizes inductive reasoning from observed clinical outcomes, lends support to the hypothesis of metabolic reprogramming in cancer treatment. By addressing both metabolic and environmental disruptions, this review suggests that considering cancer as primarily a metabolic disorder could lead to more targeted and effective treatment strategies, potentially improving outcomes for patients with advanced-stage cancers.
- 26 September 2024
- Published by MDPI AG in Biomedicines
- Vol. 12 (10) , 2197
Open AccessHow Does Cancer Occur? How Should It Be Treated? Treatment from the Perspective of Alkalization Therapy Based on Science-Based Medicine
This review article investigates the relationship between mitochondrial dysfunction and cancer progression, emphasizing the metabolic shifts that promote tumor growth. Mitochondria are crucial for cellular energy production, but they also play a significant role in cancer progression by promoting glycolysis even under oxygen-rich conditions, a phenomenon known as the Warburg effect. This metabolic reprogramming enables cancer cells to maintain an alkaline internal pH and an acidic external environment, which are critical for their proliferation and survival in hypoxic conditions. The article also explores the acidic tumor microenvironment (TME), a consequence of intensive glycolytic activity and proton production by cancer cells. This acidic milieu enhances the invasiveness and metastatic potential of cancer cells and contributes to increased resistance to chemotherapy. Alkalization therapy, which involves neutralizing this acidity through dietary modifications and the administration of alkalizing agents such as sodium bicarbonate, is highlighted as an effective strategy to counteract these adverse conditions and impede cancer progression. Integrating insights from science-based medicine, the review evaluates the effectiveness of alkalization therapy across various cancer types through clinical assessments. Science-based medicine, which utilizes inductive reasoning from observed clinical outcomes, lends support to the hypothesis of metabolic reprogramming in cancer treatment. By addressing both metabolic and environmental disruptions, this review suggests that considering cancer as primarily a metabolic disorder could lead to more targeted and effective treatment strategies, potentially improving outcomes for patients with advanced-stage cancers.
- Open Access
- 10 June 2024
- Published by MDPI AG in Pharmaceutics
- Vol. 16 (6) , 787
Exploring the Potential Use of Natural Products Together with Alkalization in Cancer Therapy
Cancer treatment is a significant focus in medicine, owing to the increasing global incidence of cancers. Patients with advanced cancers that do not respond to conventional therapies have limited options and an unfavorable prognosis. Consequently, researchers are investigating complementary approaches to conventional treatments. One such approach is alkalization therapy, which aims to neutralize the acidic tumor microenvironment (TME) by increasing its pH level. The acidic TME promotes inflammation, tumor progression, and drug resistance. Alkalization therapy has been demonstrated to be effective for various cancers. In addition, natural products, such as triterpenoids, parthenolides, fulvic acid, Taxus yunnanensis, and apple pectin have the potential to alleviate symptoms, maintain physical fitness, and improve treatment outcomes of cancer patients through their anti-inflammatory, antioxidant, and anticancer properties. In this review, we focus on the effects of alkalization therapy and natural products on cancer. Furthermore, we present a case series of advanced cancer patients who received alkalization therapy and natural products alongside standard treatments, resulting in long-term survival. We posit that alkalization therapy together with supplementation with natural products may confer benefits to cancer patients, by mitigating the side effects of chemotherapy and complementing standard treatments. However, further research is warranted to validate these clinical findings.
- 10 June 2024
- Published by MDPI AG in Pharmaceutics
- Vol. 16 (6) , 787
Open AccessExploring the Potential Use of Natural Products Together with Alkalization in Cancer Therapy
Cancer treatment is a significant focus in medicine, owing to the increasing global incidence of cancers. Patients with advanced cancers that do not respond to conventional therapies have limited options and an unfavorable prognosis. Consequently, researchers are investigating complementary approaches to conventional treatments. One such approach is alkalization therapy, which aims to neutralize the acidic tumor microenvironment (TME) by increasing its pH level. The acidic TME promotes inflammation, tumor progression, and drug resistance. Alkalization therapy has been demonstrated to be effective for various cancers. In addition, natural products, such as triterpenoids, parthenolides, fulvic acid, Taxus yunnanensis, and apple pectin have the potential to alleviate symptoms, maintain physical fitness, and improve treatment outcomes of cancer patients through their anti-inflammatory, antioxidant, and anticancer properties. In this review, we focus on the effects of alkalization therapy and natural products on cancer. Furthermore, we present a case series of advanced cancer patients who received alkalization therapy and natural products alongside standard treatments, resulting in long-term survival. We posit that alkalization therapy together with supplementation with natural products may confer benefits to cancer patients, by mitigating the side effects of chemotherapy and complementing standard treatments. However, further research is warranted to validate these clinical findings.
- Open Access
- 26 February 2024
- Published by MDPI AG in Preprints.org
Exploring the Potential Use of Natural Products Together with Alkalization in Cancer Therapy
Cancer treatment is a significant focus in medicine owing to the increasing global incidence. Patients with advanced cancers that do not respond to conventional therapies have limited options and an unfavorable prognosis. Consequently, researchers are investigating complementary approaches to conventional treatments. One such approach is alkalization therapy, which aims to neutralize the acidic tumor microenvironment (TME) by increasing its pH level. The acidic TME promotes inflammation, tumor progression, and drug resistance. Alkalization therapy has been demonstrated to be effective for various cancers. In addition, natural products, such as triterpenoids, parthenolides, fulvic acid, Taxus yunnanensis, and apple pectin have the potential to alleviate symptoms, maintain physical fitness, and improve treatment outcomes of cancer patients through their anti-inflammatory, antioxidant, and anticancer properties. In this review, we focus on the effects of alkalization therapy and natural products on cancer. Furthermore, we present a case series of advanced cancer patients who received alkalization therapy and natural products alongside standard treatments, resulting in long-term survival. We posit that alkalization therapy together with the supplementation of natural products may confer benefits to cancer patients by mitigating the side effects of chemotherapy and complementing standard treatments. However, further research is warranted to validate these clinical findings.
- 26 February 2024
- Published by MDPI AG in Preprints.org
Open AccessExploring the Potential Use of Natural Products Together with Alkalization in Cancer Therapy
Cancer treatment is a significant focus in medicine owing to the increasing global incidence. Patients with advanced cancers that do not respond to conventional therapies have limited options and an unfavorable prognosis. Consequently, researchers are investigating complementary approaches to conventional treatments. One such approach is alkalization therapy, which aims to neutralize the acidic tumor microenvironment (TME) by increasing its pH level. The acidic TME promotes inflammation, tumor progression, and drug resistance. Alkalization therapy has been demonstrated to be effective for various cancers. In addition, natural products, such as triterpenoids, parthenolides, fulvic acid, Taxus yunnanensis, and apple pectin have the potential to alleviate symptoms, maintain physical fitness, and improve treatment outcomes of cancer patients through their anti-inflammatory, antioxidant, and anticancer properties. In this review, we focus on the effects of alkalization therapy and natural products on cancer. Furthermore, we present a case series of advanced cancer patients who received alkalization therapy and natural products alongside standard treatments, resulting in long-term survival. We posit that alkalization therapy together with the supplementation of natural products may confer benefits to cancer patients by mitigating the side effects of chemotherapy and complementing standard treatments. However, further research is warranted to validate these clinical findings.
- Open Access
Potential of Alkalization Therapy for the Management of Metastatic Pancreatic Cancer: A Retrospective Study
Current treatments for patients with pancreatic cancer offer limited benefits. In this study, we applied alkalization therapy, which was efficacious for other solid tumors at our clinic, to stage 4 pancreatic cancer patients, and investigated its effect on disease prognosis. Patients with metastatic pancreatic cancer who were treated at Karasuma Wada Clinic in Kyoto, Japan, between January 2011 and April 2022, were included in the study. All patients received alkalization therapy (a combination of an alkaline diet, bicarbonate, and citric acid administration), alongside standard chemotherapy. Urine samples were collected to assess urine pH as a marker of whole-body alkalization. In the 98 patients analyzed, the median overall survival (OS) from the time of diagnosis was 13.2 months. Patients with a mean urine pH of 7.5 or greater had a median OS of 29.9 months, compared with 15.2 months for those with a mean urine pH of 6.5 to 7.5, and 8.0 months for those with a mean urine pH of less than 6.5, which suggests a trend of a longer OS in patients with a higher urine pH (p = 0.0639). Alkalization therapy may offer a viable approach to extending the survival of stage 4 pancreatic cancer patients, who typically have an unfavorable prognosis.
Open AccessPotential of Alkalization Therapy for the Management of Metastatic Pancreatic Cancer: A Retrospective Study
Current treatments for patients with pancreatic cancer offer limited benefits. In this study, we applied alkalization therapy, which was efficacious for other solid tumors at our clinic, to stage 4 pancreatic cancer patients, and investigated its effect on disease prognosis. Patients with metastatic pancreatic cancer who were treated at Karasuma Wada Clinic in Kyoto, Japan, between January 2011 and April 2022, were included in the study. All patients received alkalization therapy (a combination of an alkaline diet, bicarbonate, and citric acid administration), alongside standard chemotherapy. Urine samples were collected to assess urine pH as a marker of whole-body alkalization. In the 98 patients analyzed, the median overall survival (OS) from the time of diagnosis was 13.2 months. Patients with a mean urine pH of 7.5 or greater had a median OS of 29.9 months, compared with 15.2 months for those with a mean urine pH of 6.5 to 7.5, and 8.0 months for those with a mean urine pH of less than 6.5, which suggests a trend of a longer OS in patients with a higher urine pH (p = 0.0639). Alkalization therapy may offer a viable approach to extending the survival of stage 4 pancreatic cancer patients, who typically have an unfavorable prognosis.